S
Stefan Balabanov
Researcher at University of Zurich
Publications - 94
Citations - 3159
Stefan Balabanov is an academic researcher from University of Zurich. The author has contributed to research in topics: Imatinib & Haematopoiesis. The author has an hindex of 31, co-authored 85 publications receiving 2545 citations. Previous affiliations of Stefan Balabanov include Erasmus University Rotterdam & University of Glasgow.
Papers
More filters
Journal ArticleDOI
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.
Sarah Minner,Corinna Wittmer,Markus Graefen,Georg Salomon,Thomas Steuber,Alexander Haese,Hartwig Huland,Carsten Bokemeyer,Emre F. Yekebas,Judith Dierlamm,Stefan Balabanov,Ergin Kilic,Waldemar Wilczak,Ronald Simon,Guido Sauter,Thorsten Schlomm +15 more
TL;DR: This study was undertaken, to gain more insight on the role of PSMA in early prostate cancer and its distribution in various normal tissues.
Journal ArticleDOI
Polyamines Control eIF5A Hypusination, TFEB Translation, and Autophagy to Reverse B Cell Senescence
Hanlin Zhang,Ghada Alsaleh,Jack Feltham,Yizhe Sun,Gennaro Napolitano,Thomas Riffelmacher,Philip D. Charles,Lisa Frau,Philip Hublitz,Zhanru Yu,Shabaz Mohammed,Andrea Ballabio,Stefan Balabanov,Jane Mellor,Anna Katharina Simon +14 more
TL;DR: An unexpected autophagy regulatory mechanism mediated by eIF5A at the translational level, which can be harnessed to reverse immune senescence in humans is revealed.
Journal ArticleDOI
Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation
Daniel J. Puleston,Daniel J. Puleston,Michael D. Buck,Ramon I. Klein Geltink,Ryan Kyle,George Caputa,David O’Sullivan,Alanna M. Cameron,Angela Castoldi,Yaarub Musa,Agnieszka M. Kabat,Ying Zhang,Lea J. Flachsmann,Cameron S. Field,Annette E. Patterson,Stefanie Scherer,Francesca Alfei,Francesc Baixauli,S. Kyle Austin,Beth Kelly,Mai Matsushita,Jonathan D. Curtis,Katarzyna M. Grzes,Matteo Villa,Mauro Corrado,David E. Sanin,Jing Qiu,Nora Pällman,Katelyn Paz,Maria Elena Maccari,Bruce R. Blazar,Gerhard Mittler,Joerg M. Buescher,Dietmar Zehn,Sabine Rospert,Edward J. Pearce,Edward J. Pearce,Stefan Balabanov,Erika L. Pearce +38 more
TL;DR: It is shown that acute inhibition of this pathway blunts OXPHOS-dependent alternative activation, while leaving aerobic glycolysis-dependent classical activation intact, which might have implications for therapeutically controlling macrophage activation by targeting the polyamine-eIF5A-hypusine axis.
Journal ArticleDOI
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Artur Gontarewicz,Stefan Balabanov,Gunhild Keller,Riccardo Colombo,Alessio Graziano,Enrico Pesenti,Daniel Benten,Carsten Bokemeyer,Walter Fiedler,Jürgen Moll,Tim H. Brümmendorf +10 more
TL;DR: PHA-739358 represents a promising new strategy for treatment of IM-resistant BCR-ABL-positive leukemias, including those harboring the T315I mutation, which is a major challenge in the treatment of chronic myeloid leukemia.
Journal ArticleDOI
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Stefan Balabanov,Artur Gontarewicz,Patrick Ziegler,Ulrike Hartmann,Winfried Kammer,Mhairi Copland,Ute Brassat,Martin Priemer,Ilona Hauber,Thomas Wilhelm,Gerold Schwarz,Lothar Kanz,Carsten Bokemeyer,Joachim Hauber,Tessa L. Holyoake,Alfred Nordheim,Tim H. Brümmendorf +16 more
TL;DR: The inhibition of eIF5A hypusination as a promising new approach for combination therapy in BCR-ABL-positive leukemias is identified through a comparative proteomics approach and further functional analysis.